TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03894059

Intervention type: OTHER
Intervention: Educational Intervention
Description: Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
Study: NCT00792142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given orally

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Performed on baseline and post transplant bone marrow specimens

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Performed on baseline and post transplant bone marrow specimens

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
Study: NCT03812718

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube (ETT)
Description: After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Description: After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
Study: NCT01349283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepavaxGene (thiomersal free)
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepavaxGene (thiomersal free)
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepavaxGene (thiomersal free)
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
Study: NCT04542629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiTUXimab Injection [Rituxan]
Description: 375 MG/M2 /WEEK INFUSION
Study: NCT02909322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Hydromorphone
Description: Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ropivacaine and Hydromorphone
Description: Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
Study: NCT02138318

Intervention type: OTHER
Group type: OTHER
Intervention: High definition (HD) endoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: chromoendoscopy
Study: NCT02233049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT00529841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium acetate
Description: Subcutaneous administration of medication via insulin pump
Study: NCT03377348

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
Description: intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
Study: NCT04904523

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test:Blood test
Description: Drop of blood for RNA and metabolic analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test:Blood test
Description: Drop of blood for RNA and metabolic analysis
Study: NCT02501889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walnut-rich weight loss diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight loss diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study: NCT01416012

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy (standard)
Description: This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Gait training in Individualized sessions
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kinect
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Xbox Kinect
Description: The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
Study: NCT02674022

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal supplement
Description: Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal supplement
Description: Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
Study: NCT02136875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose of Salmeterol + Fluticasone Propionate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education on the use of a self-administered prescription for exacerbation.
Description: Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-administered prescription
Description: An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days
Study: NCT01037478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resminostat (4SC-201)
Description: oral administration
Study: NCT00648531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balsalazide Disodium Capsules 750 mg
Description: 3x750mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colazal® Capsules 750 mg
Description: 3x750mg, single dose fasting
Study: NCT03320239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk assessment and tailored suggestions
Description: The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV risk behavior assessment
Description: It only contains HIV risk behavior assessment and routine education

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: It only contains HIV/AIDS knowledge assessment and routine education
Study: NCT00595582

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: curcumin + bioperine
Description: Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
Study: NCT02669290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided
Description: LV lead placement will be guided by left ventricular systolic function information from MUGA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-guided
Description: LV lead placement will be conventional posterolateral placement
Study: NCT04691466

Intervention type: PROCEDURE
Intervention: Joint replacement
Description: Routinely performed hip- or knee replacement

Intervention type: PROCEDURE
Intervention: Joint replacement
Description: Routinely performed hip- or knee replacement
Study: NCT01236404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Description: Once weekly injections for up to four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
Description: Once weekly injections for up to four weeks
Study: NCT01296958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community education campaign
Description: Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
Study: NCT01312766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropins
Description: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menotropins
Description: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
Study: NCT00624117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive exercise
Description: home-based exercise program, 2 to 3 exercise sessions per week
Study: NCT03390907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid APC
Description: Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
Study: NCT00792142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
Study: NCT00691210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells.
Study: NCT00632476

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once a day
Study: NCT00632476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: A 500-mg vitamin C capsule once a day
Study: NCT00691210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor.
Study: NCT01306617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: capsules
Study: NCT02114970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized- paper consent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized- Tablet-delivered consent

Intervention type: OTHER
Group type: OTHER
Intervention: Focus Group- paper and tablet consent
Study: NCT02125539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigating my Journey program
Description: The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
Study: NCT01254357

Intervention type: OTHER
Intervention: Questionnaire self report
Description: Burn specific outcome measurement and global health measurement
Study: NCT01122199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 + AMG479
Description: Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
Study: NCT03481959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods).